MediPharm Posts Q1 2021 Results: What Cannabis Stock Investors Need To Know
Adjusted EBITDA, a non-IFRS measure, came in negative at roughly CA$6.16 million, representing an improvement from a CA$8.77 million loss in the prior quarter and a loss of CA$5.66 million in the same quarter of 2020.
Greg Hunter, CFO of the Barrie, Ontario-based company, called the quarter a "cross-over period to our future state as the preferred global cannabis API provider to medical and wellness markets."
Q1 2021 Highlights
- Gross profit was negative at CA$680 000 compared to a negative gross profit of CA$24.7 million in the previous quarter and CA$10.9 million in the same period of 2020.
- A negative gross margin was 12%, compared to a negative gross margin of 408% in the last three months of 2020 and 98% in the prior year's corresponding quarter.
- Net loss amounted to approximately CA$13.9 million, after shrinking by 55% sequentially and 37% year-over-year.
- International sales rose to CA$1.8 million over the last three months of 2020, to CA$2.1 million in the first quarter of 2021.
- The company achieved more than CA$1.5 million in cost savings.
- As of March 31, the company had CA$42.1 million in cash and cash equivalents.
"We commenced 2021 focused on establishing our presence as a pharmaceutical company while ramping up and significantly growing our international sales," Hunter added.
In October, MediPharm Labs inked a deal to supply GMP-certified medical cannabis products to German pharmaceutical giant Stada Arzneimittel AG.
Six months later, in April, the company expanded its reach in the German market by signing a two-year supply agreement with the subsidiary of the multi-country medical and recreational cannabis operator IM Cannabis (CSE:IMCC) (NASDAQ:IMCC), which agreed to expand its product offering in Germany in 2021.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.